MedTrace Logo

STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma

NCT04098432 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-09-23

No results posted yet for this study

Summary

Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

Conditions

  • Locally Advanced Unresectable Pancreatic Adenocarcinoma

Interventions

DRUG

Nivolumab

Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity

RADIATION

Stereotactic radiotherapy

The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • GCP-Service International s.r.o.

    collaborator UNKNOWN

  • University Hospital Hradec Kralove

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-03
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04098432 on ClinicalTrials.gov